• Je něco špatně v tomto záznamu ?

Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients

A. Poprach, O. Fiala, R. Chloupkova, B. Melichar, R. Lakomy, K. Petrakova, M. Zemanova, K. Kopeckova, O. Slaby, H. Studentova, J. Kopecký, I. Kiss, J. Finek, L. Dusek, T. Buchler,

. 2018 ; 38 (1) : 449-456.

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18010227

BACKGROUND: Pazopanib is approved for the first-line treatment of patients with metastatic renal cell carcinoma (mRCC). The present study was a retrospective registry-based analysis of 426 patients with mRCC treated with pazopanib as first-line targeted therapy. PATIENTS AND METHODS: The data were obtained from the Renal Cell Carcinoma Information system registry. Patient baseline parameters, treatment course and outcomes, and toxicity were analysed. RESULTS: Median progression-free and overall survival were 12.9 (95% confidence interval(CI)=11.0-14.8) months and 33.2 (95% CI=29.9-36.4) months, respectively. Overall response rate and disease control rate were 25.1% and 57.4%, respectively. Adverse events led to discontinuation of treatment in 37 (12.1%) patients. CONCLUSION: The results confirm that pazopanib is an effective and safe first-line targeted treatment in patients with mRCC. Both the International mRCC Database Consortium and the Memorial Sloan Kettering models were valid predictors of prognosis and nephrectomy was associated with improved survival.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18010227
003      
CZ-PrNML
005      
20190424144034.0
007      
ta
008      
180404s2018 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/anticanres.12243 $2 doi
035    __
$a (PubMed)29277808
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Poprach, Alexandr $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic. Faculty of Medicine, Masaryk University Brno, Brno, Czech Republic.
245    10
$a Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients / $c A. Poprach, O. Fiala, R. Chloupkova, B. Melichar, R. Lakomy, K. Petrakova, M. Zemanova, K. Kopeckova, O. Slaby, H. Studentova, J. Kopecký, I. Kiss, J. Finek, L. Dusek, T. Buchler,
520    9_
$a BACKGROUND: Pazopanib is approved for the first-line treatment of patients with metastatic renal cell carcinoma (mRCC). The present study was a retrospective registry-based analysis of 426 patients with mRCC treated with pazopanib as first-line targeted therapy. PATIENTS AND METHODS: The data were obtained from the Renal Cell Carcinoma Information system registry. Patient baseline parameters, treatment course and outcomes, and toxicity were analysed. RESULTS: Median progression-free and overall survival were 12.9 (95% confidence interval(CI)=11.0-14.8) months and 33.2 (95% CI=29.9-36.4) months, respectively. Overall response rate and disease control rate were 25.1% and 57.4%, respectively. Adverse events led to discontinuation of treatment in 37 (12.1%) patients. CONCLUSION: The results confirm that pazopanib is an effective and safe first-line targeted treatment in patients with mRCC. Both the International mRCC Database Consortium and the Memorial Sloan Kettering models were valid predictors of prognosis and nephrectomy was associated with improved survival.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a inhibitory angiogeneze $x škodlivé účinky $x terapeutické užití $7 D020533
650    _2
$a karcinom z renálních buněk $x farmakoterapie $x patologie $x chirurgie $7 D002292
650    _2
$a Česká republika $7 D018153
650    _2
$a databáze faktografické $7 D016208
650    _2
$a přežití po terapii bez příznaků nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a indoly $x terapeutické užití $7 D007211
650    _2
$a nádory ledvin $x farmakoterapie $x patologie $x chirurgie $7 D007680
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nefrektomie $7 D009392
650    _2
$a protoonkogenní proteiny c-kit $x antagonisté a inhibitory $7 D019009
650    _2
$a pyrimidiny $x škodlivé účinky $x terapeutické užití $7 D011743
650    _2
$a pyrroly $x terapeutické užití $7 D011758
650    _2
$a receptory růstového faktoru odvozeného z trombocytů $x antagonisté a inhibitory $7 D017479
650    _2
$a receptory vaskulárního endoteliálního růstového faktoru $x antagonisté a inhibitory $7 D040262
650    _2
$a registrace $7 D012042
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a sulfonamidy $x škodlivé účinky $x terapeutické užití $7 D013449
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a Fiala, Ondrej $u Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Pilsen, Czech Republic. Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
700    1_
$a Chloupková, Renata $7 xx0235127 $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Melichar, Bohuslav $u Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic.
700    1_
$a Lakomy, Radek $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic. Faculty of Medicine, Masaryk University Brno, Brno, Czech Republic.
700    1_
$a Petrakova, Katarina $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic. Faculty of Medicine, Masaryk University Brno, Brno, Czech Republic.
700    1_
$a Zemanova, Milada $u Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
700    1_
$a Kopeckova, Katerina $u Department of Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
700    1_
$a Slaby, Ondrej $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic. Faculty of Medicine, Masaryk University Brno, Brno, Czech Republic.
700    1_
$a Studentova, Hana $u Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic.
700    1_
$a Kopecký, Jindrich $u Department of Oncology, University Hospital in Hradec Králové, Hradec Králové, Czech Republic.
700    1_
$a Kiss, Igor $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic. Faculty of Medicine, Masaryk University Brno, Brno, Czech Republic.
700    1_
$a Finek, Jindrich $u Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Pilsen, Czech Republic.
700    1_
$a Dusek, Ladislav $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
700    1_
$a Buchler, Tomas $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic tomas.buchler@ftn.cz.
773    0_
$w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 38, č. 1 (2018), s. 449-456
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29277808 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20190424144113 $b ABA008
999    __
$a ok $b bmc $g 1287712 $s 1007039
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 38 $c 1 $d 449-456 $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
LZP    __
$a Pubmed-20180404

Najít záznam

Citační ukazatele

Možnosti archivace